What are the current data, recent updates, and guideline recommendations for the use of anifrolumab (type I interferon receptor antagonist) in adults with moderate‑to‑severe systemic lupus erythematosus?

Anifrolumab in Systemic Lupus Erythematosus: Current Evidence and Guidelines

Anifrolumab is a type I interferon receptor antagonist approved for moderate-to-severe extrarenal SLE in adults receiving standard therapy, with robust evidence demonstrating superior efficacy over placebo in achieving disease control and enabling glucocorticoid reduction. 1

FDA-Approved Indication and Dosing

Anifrolumab (SAPHNELO) is FDA-approved at 300 mg intravenously every 4 weeks over 30 minutes for adults with moderate-to-severe SLE receiving standard therapy. 2 The drug is NOT recommended for severe active lupus nephritis or severe active CNS lupus, as efficacy has not been established in these populations. 2

A subcutaneous formulation (120 mg weekly) has recently demonstrated efficacy in phase 3 trials and may offer an alternative administration route. 3

Efficacy Data from Recent Guidelines

Extrarenal Disease (Primary Indication)

The 2024 EULAR systematic review informing updated SLE management guidelines establishes anifrolumab's efficacy through high-quality evidence:

• BICLA Response: Pooled analysis shows significantly higher response rates versus placebo (OR 2.25,95% CI 1.72-2.95) 1
• Disease Flare Reduction: Anifrolumab reduces annualized flare rates (rate ratio 0.75,95% CI 0.60-0.95) and prolongs time to first flare (HR 0.70,95% CI 0.55-0.89) 1
• Glucocorticoid-Sparing Effect: 50.5% of patients on ≥10 mg/day prednisone at baseline achieved sustained reduction to ≤7.5 mg/day versus 31.8% with placebo (Δ 18.7%, p<0.001) 1

Organ-Specific Efficacy

Mucocutaneous Disease: Post-hoc analyses demonstrate CLASI-A 50 response rates exceeding placebo by >20%, reaching nearly 30% difference in the MUSE trial. 1

Musculoskeletal Disease: Anifrolumab achieves 12.6% greater reduction in swollen/tender joints (95% CI 2.4-22.9%) compared to placebo. 1

Hematologic Disease: Post-hoc TULIP analysis shows 25% difference in hematologic response rates favoring anifrolumab. 1

Lupus Nephritis (Limited Evidence)

The phase II TULIP-LN trial did NOT meet its primary endpoint for combined anifrolumab groups. However, the intensified regimen (900 mg × 3 doses, then 300 mg) showed 45.5% complete response versus 31.1% with placebo—this difference was not statistically significant in the primary analysis. 1 Given the lack of robust efficacy data and safety concerns (see below), anifrolumab should not be used for active lupus nephritis. 2

Real-World Evidence and Long-Term Data

Recent real-world cohorts (2026) demonstrate impressive effectiveness:

• LLDAS attainment: 75.8% at 6-12 months (95% CI 68.4-82.5%) 4
• DORIS remission: 50% achieved by month 12 5
• Glucocorticoid reduction: 72.5% achieved >50% dose reduction; 11/13 patients reached ≤5 mg/day prednisolone 4, 5
• Drug persistence: 65% at 12 months 5

Long-term extension data (up to 4 years) confirm sustained efficacy with stable safety profiles. 4

Safety Profile and Critical Warnings

Herpes Zoster Risk (Most Important Safety Signal)

Anifrolumab significantly increases herpes zoster (HZ) risk: 6.4% versus 1.4% with placebo in TULIP trials (OR 3.45-4.74 across meta-analyses). 1, 4, 6 This risk:

• Occurs in both interferon-high and interferon-low patients 1
• Decreases over time (6.8 per 100 patient-years in year 1, dropping to 2.9 in year 4) 1
• Consists mainly of mild-to-moderate cases 4
• Mandates HZ vaccination before initiating therapy 4

Lupus Nephritis Safety Concern

In TULIP-LN, anifrolumab showed increased VZV infection rates (16.7% vs 8.2% placebo), raising particular safety concerns in this population. 1 This further supports avoiding anifrolumab in active lupus nephritis.

Other Safety Considerations

• Serious infections: FDA label warns of serious/fatal infections including COVID-19; avoid initiating during active infection 2
• Contraindication: History of anaphylaxis with anifrolumab 2
• Hypersensitivity reactions: Anaphylaxis and angioedema reported 2
• Overall serious adverse events: No significant increase versus placebo (OR 0.82, p=0.25) 4
• Avoid live vaccines during treatment 2

Patient Selection and Predictors of Response

Anifrolumab demonstrates superior efficacy in patients with:

• Abnormal serological markers at baseline (low C3/C4 and/or elevated anti-dsDNA antibodies) 1
• High interferon gene signature (though benefit extends to interferon-low patients) 1
• No requirement for prior immunosuppressant failure: Recent analysis confirms efficacy regardless of prior IS use, with potentially more favorable safety in IS-inexperienced patients 7

Comparative Effectiveness

A 2026 network meta-analysis comparing anifrolumab and belimumab found:

• SRI-4 responses: Similar between drugs (anifrolumab OR 1.78 vs belimumab OR 1.62, no significant difference) 6
• BICLA response: Anifrolumab superior to belimumab (OR 1.56,95% CI 1.10-2.21), though this relies on indirect comparison with moderate certainty 6
• HZ risk: Significantly higher with anifrolumab versus belimumab (OR 4.74,95% CI 2.00-11.21) 6

Clinical Algorithm for Anifrolumab Use

Initiate anifrolumab when:

1. Patient has moderate-to-severe extrarenal SLE despite standard therapy
2. Particularly consider if mucocutaneous, musculoskeletal, or hematologic manifestations predominate
3. Patient requires glucocorticoid doses >7.5 mg/day that need tapering
4. Serologically active disease (low complement, elevated anti-dsDNA)
5. Administer HZ vaccination before starting therapy

Do NOT use anifrolumab for:

• Severe active lupus nephritis (use belimumab or voclosporin instead) 1
• Severe active CNS lupus 2
• Active serious infections 2
• History of anaphylaxis to anifrolumab 2

Monitor for:

• Herpes zoster (educate patients on early recognition)
• Respiratory infections
• Infusion reactions
• Disease activity using validated measures (SLEDAI-2K, BICLA)

Recent Updates (2024-2026)

• 2024 EULAR guidelines incorporate anifrolumab as evidence-based option for extrarenal SLE 1
• Subcutaneous formulation (120 mg weekly) demonstrated efficacy in 2025 phase 3 trial 3
• Real-world data (2026) confirms trial efficacy translates to clinical practice with 75.8% LLDAS attainment 4, 5
• Mechanistic insights (2026) show anifrolumab reduces low-density neutrophils and interferon-driven chemokines 5